Akeso Biomedical

Waltham, MA 02451, US
Pharmaceuticals
www.akesobiomedical.com

Akeso Biomedical is developing new solutions for the treatment of bacterial infections and microbial biofilms using a broad-spectrum iron complex chemistry (“Fe3C”) discovered by researchers at the University of Nottingham, UK. The Company’s product pipeline includes Fe3C compounds for the prevention of foodborne illnesses, and the treatment of bacterial infections including infected chronic wounds and medical devices. Each year in the US, it is estimated that there are about 3.2 million cases of foodborne illness due to bacteria, 2 million nosocomial (hospital acquired) infections, and that up to 6% of implanted medical devices become infected. The cost of treating foodborne bacterial infections is estimated to be $9 billion. The cost of treating hospital-acquired infections is now a staggering $30 billion.

Akeso’s lead Fe3C product is a feed additive designed to prevent food poisoning by Campylobacter, a bacteria that causes diarrhea, abdominal cramps, fever and vomiting for up to 6 days. The infection can also lead to irritable bowel syndrome, reactive arthritis, Guillain-Barré syndrome, and can even be deadly for some patients. The bacterium is commonly transmitted to humans from poultry, lives in the intestines of chickens, and after factory processing is a common contaminate found on about 65% of chickens sold by grocery stores. In the EU, Campylobacter causes more cases of foodborne illness than Salmonella, E. coli and Listeria combined with an estimated 280,000 cases in the UK and 9 million in the EU.

Akeso’s product pipeline is evolving to include the use of the Fe3C technology to prevent the formation of bacterial biofilms on medical devices, and to treat biofilm infections. According to the National Institutes of Health (NIH), biofilms account for over 80% of microbial infection in the body, and are estimated to account for almost 50% of the 2 million hospital-acquired infections.

General Information

 
 
 
 
 

Social Links

Company Industry

Select Industry:

Company Description

0 / 250
 
0 / 2000
 

Summary

Prior Year Revenue Current Year Revenue Next Year Revenue
Company Age Employees Sub-Industry
3 years, 9 months 1 Other Pharmaceuticals
Company Type Stock Exchange Stock Symbol
Privately-Held - -

Company Financials

Viewable by EquityNet investors only

Company Age & Size

Stock Exchange

Is this company privately-held or publicly-traded?

Products / Services

0 / 1000
Fe3C Compounds to Prevent Bacterial Infections

Fe3C Compounds are a new class of iron complexes that are being developed to fight bacterial infections. These compounds have broad-spectrum activity, and bind to bacteria to prevent infection. Fe3C compounds are being developed initially as feed additives to prevent infection of poultry by the bacteria, Campylobacter. Other potential applications of Fe3C include treatment of medical devices to prevent biofilm formation, and treatment of bacterial infections in both humans and pets.

Management

0 / 1000
Chief Executive Officer
Simon Williams

Simon Williams, CEO, has over 20 years of experience in creating, organizing, developing, licensing, financing and managing new medical and chemical technologies from early stage research through to commercially viable products. Prior to Akeso Biomedical, Dr. Williams was the President of Tepha, Inc., where he formulated a product development strategy for a new absorbable biomaterials technology that led to FDA regulatory clearance of 17 novel medical device products over 5 years. Products developed by Tepha included CR Bard’s Phasix™ hernia repair mesh, B. Braun Surgical’s MonoMax® absorbable sutures, Tornier’s Phantom Fiber™ for ligament and tendon repair, and Galatea’s GalaFLEX® mesh for plastic and reconstructive surgery. Dr. Williams is a cofounder of the bioscience company, Metabolix (NASDAQ: MBLX). Dr. Williams was a NATO postdoctoral fellow at M.I.T., and completed a Ph.D. in organic chemistry at Cambridge University, England. He is a Fellow of the Royal Society of Medicine.

Funding

33%

Funding Goal$750,000

Funding Raised So Far$250,000

Funding Commitments

Funding Remaining$500,000

Funding TypeEquity

Pre-Money Valuation

Investor Ownership

Interest / Dividend

Previous Funding

General Funding

Showing your General Funding information publicly may constitute general solicitation. General solicitation is a new commonly-used way for companies to raise funding. To learn about general solicitation, consult your legal counsel. If you uncheck this box, your General Funding information will be viewable to only EquityNet investors.

Private Funding

Viewable by EquityNet investors only

Video

Akeso Biomedical Image 1
Akeso Biomedical Image 2
Akeso Biomedical Image 3
Akeso Biomedical Image 4
Akeso Biomedical Image 5
Akeso Biomedical Image 6
Akeso Biomedical Image 7
Akeso Biomedical Image 8
Akeso Biomedical Image 9

Images

Documents

Complete a Business Plan in EquityNet

Your EquityNet business plan is only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab. Investors prefer an EquityNet business plan. Entering a plan is highly educational and improves your appeal to investors.

Upload Documents

Document file names will be viewable by EquityNet investors and business supporters only. Actual documents are only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab.

Share Your Public Profile Page

Users who follow all these tips increase their fundraising odds substantially.

  • Email your public page to all your LinkedIn contacts.
    • Post your page to your LinkedIn profile page.
  • Email your public page to all your Facebook contacts.
    • Post your page to your Facebook profile page.
  • Email your public page to all your Twitter contacts.
    • Post your page to your Twitter profile page.
  • Put your public page up on your website.
    • Don't have a website yet? Use this page as your site!
  • Share your page link anywhere there's a listing for your company.
    • Press Releases, Crunchbase, Wikipedia, Blogs, etc...
  • Email your public page to all your email contacts.
    • Use Outlook, Gmail, Yahoo Mail, Hotmail, etc...

Your Public Profile Page:

Would you like to share your public profile page with your email contacts?